Arrowhead Research Corp. (ARWR) Trading Down 4.3%
Shares of Arrowhead Research Corp. (NASDAQ:ARWR) dropped 4.3% during trading on Wednesday . The company traded as low as $5.60 and last traded at $5.60, with a volume of 280,006 shares traded. The stock had previously closed at $5.85.
ARWR has been the topic of a number of recent analyst reports. Vetr downgraded shares of Arrowhead Research Corp. from a “strong-buy” rating to a “buy” rating and set a $6.49 price target on the stock. in a research report on Wednesday, April 13th. Jefferies Group restated a “hold” rating and set a $4.75 price target on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. Finally, Chardan Capital initiated coverage on shares of Arrowhead Research Corp. in a research report on Thursday, May 19th. They set a “buy” rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.27.
The firm’s market cap is $335.78 million. The stock has a 50-day moving average of $5.77 and a 200 day moving average of $5.05.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Equities analysts expect that Arrowhead Research Corp. will post ($1.40) earnings per share for the current fiscal year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.